Literature DB >> 4022205

Plasma exchange in the treatment of mesangiocapillary glomerulonephritis.

E McGinley, R Watkins, A McLay, J M Boulton-Jones.   

Abstract

9 patients with primary glomerulopathies and slowly progressive renal failure were treated by regular plasma exchanges without immunosuppressive drug therapy. All 3 patients with the subendothelial type of mesangiocapillary glomerulonephritis (MCGN-I) had no progression of their renal failure while undergoing plasma exchanges. The creatinine rose when treatment was stopped and fell again in 2 patients who restarted plasma exchange. 2 patients with hypocomplementaemia and dense deposit disease (MCGN-II) and all 3 patients with idiopathic membranous nephropathy (IMN) did not benefit. 1 patient with normo-complementaemic MCGN-II had some improvement in renal function which lasted 18 months. Proteinuria fell or was unchanged during the 1st month of plasma exchange in the 4 who improved and increased in the 5 who did not. The response to plasma exchanges could not be attributed to removal of circulatory complexes or changes in reticulo-endothelial function. Regular 2.8-litre plasma exchanges using 4.3% immunoalbumin proved to be safe for periods up to 44 months. Regular plasma exchange appears to prevent progression to renal failure in patients with MCGN-I.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4022205     DOI: 10.1159/000183504

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  7 in total

Review 1.  C3 Glomerulopathy.

Authors:  Magdalena Riedl; Paul Thorner; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

Review 2.  The treatment of immune glomerular disease.

Authors:  D G Williams
Journal:  Springer Semin Immunopathol       Date:  1987

3.  Aluminium bone disease in patients receiving plasma exchange with contaminated albumin.

Authors:  D Maharaj; G S Fell; B F Boyce; J P Ng; G D Smith; J M Boulton-Jones; R L Cumming; J F Davidson
Journal:  Br Med J (Clin Res Ed)       Date:  1987-09-19

4.  Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression.

Authors:  Karsten Häffner; Stefan Michelfelder; Martin Pohl
Journal:  Pediatr Nephrol       Date:  2015-05-19       Impact factor: 3.714

Review 5.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

Review 6.  C3 glomerulopathy and current dilemmas.

Authors:  Naoko Ito; Ryuji Ohashi; Michio Nagata
Journal:  Clin Exp Nephrol       Date:  2016-11-23       Impact factor: 2.801

Review 7.  Overview of C3 Glomerulopathy.

Authors:  Vimal Master Sankar Raj; Roberto Gordillo; Deepa H Chand
Journal:  Front Pediatr       Date:  2016-05-06       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.